

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/780,114 02/17/2004		/17/2004	Steven W. Dow	021819-000130US	8036
20350	7590	09/07/2006		EXAMINER	
TOWNSEN		WEHBE, ANNE	WEHBE, ANNE MARIE SABRINA		
EIGHTH FL		CENTER		ART UNIT	PAPER NUMBER
SAN FRAN	CISCO, CA	94111-3834	· .	1633	

DATE MAILED: 09/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	A martin and an Al					
	Application No.	Applicant(s)				
0.55	10/780,114	DOW ET AL.				
Office Action Summary	Examiner	Art Unit				
	Anne Marie S. Wehbe	1633				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tiruly apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) ☐ Responsive to communication(s) filed on 2a) ☐ This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for alloware	action is non-final.	osecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>1-34</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-34</u> are subject to restriction and/or expressions.						
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the conference of the	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:					

DETAILED ACTION

This application contains claims directed to the following patentably distinct species of isolated nucleic acids:

- a) a nucleic acid vector without an insert
- b) a fragment of a vector without a gene insert
- c) an oligonucleotide
- d) a non-coding nucleic acid sequence from a regulatory region of a DNA
- e) a non-coding nucleic acid sequence from an intron
- f) a non-coding nucleic acid sequence from a regulatory region of an RNA
- g) a nucleic acid from a coding strand of a DNA which does not express a protein/peptide
- h) a nucleic acid from an RNA that does not express a protein/peptide
- i) a non-coding nucleic acid sequence not associated with a gene.

The species are independent or distinct because each species of nucleic acid sequence has different structural, chemical, and functional properties. For example, an intronic sequence, a coding sequence, and a regulatory sequence are unrelated in structure and function. Further, a vector comprises numerous different elements not included in isolated regulatory, intronic, or coding sequences. Further, RNA and DNA are chemically distinct. As such, as search for one species is not coextensive with the search for any other species and it would therefore place an undue burden on the examiner to search and examiner all species together.

Application/Control Number: 10/780,114

Art Unit: 1633

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for

prosecution on the merits to which the claims shall be restricted if no generic claim is finally

held to be allowable. Currently, claims 1-2, 4-20, and 29-34 are generic.

This application further contains claims directed to the following patentably distinct

species of nucleic acids which encode a cytokine:

a) IL-2

b) IL-12

c) IFN-gamma

The species are independent or distinct because each species of cytokine has different

structural, chemical, and functional properties. As such, as search for one species is not

coextensive with the search for any other species and it would therefore place an undue burden

on the examiner to search and examiner all species together.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for

prosecution on the merits to which the claims shall be restricted if no generic claim is finally

held to be allowable. Currently, all claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the

species that are elected consonant with this requirement, and a listing of all claims readable

thereon, including any claims subsequently added. An argument that a claim is allowable or that

all claims are generic is considered nonresponsive unless accompanied by an election.

Page 3

Application/Control Number: 10/780,114

Art Unit: 1633

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of species to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of a species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner's supervisor, Dave Nguyen, can be reached at (571) 272-0731. For all official communications, **the new technology center fax number is (571) 273-8300**. Please note that all official communications and responses sent by fax must be directed to the

Application/Control Number: 10/780,114

Art Unit: 1633

technology center fax number. For informal, non-official communications only, the examiner's

Page 5

direct fax number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-

0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval

system (PAIR) on the internet for patent application status and history information, and for

electronic images of applications. For questions or problems related to PAIR, please call the

USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197.

Representatives are available daily from 6am to midnight (EST). When calling please have your

application serial number or patent number available. For all other customer support, please call

the USPTO call center (UCC) at 1-800-786-9199.

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D PRIMARY EXAMINER